| abstract |
A new type of D-homo-(16-en)-11 beta -aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino grouping >N SIMILAR OH or two hydrogen atoms; R<1> stands for a hydrogen atom or a methyl group; R<2> stands for a hydroxy group, a C1-C10-alkoxy or C1-C10-acyloxy group; R<11> stands for a fluorine, chlorine or bromine atom, in which case R<12> and R<13> represent together an additional bond, or R<11> stands for a straight or branched chain C1-C4alkyl residue or a hydrogen atom, in which case R<12> and R<13> each represent a hydrogen atom or together represent an additional bond; and R<3> and R<4> have the usual meanings for competitive progesterone antagonists given in the description. Also disclosed are a process for producing these new compounds, pharmaceutical compositions containing these compounds, their use for producing medicaments and new intermediate products required for carrying out the process. These new compounds have a strong affinity for the gestagen receptor and strong antigestagenous, antiglucocorticoidal, antimineralcorticoidal and antiandrogenous properties. |